MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinson’s"

  • MDS Virtual Congress 2021

    Technology use in Parkinson’s disease and parkinsonism: a multicenter survey in real-life Healthy East Lombardy Parkinson (HELP-)network

    A. Pilotto, S. Nocivelli, D. Alimenti, J. Melgari, M. Bianchi, V. de Giuli, A. Magherini, M. Rizzeti, F. Pisano, T. Di Monda, M. Gennuso, S. Gipponi, E. Cottini, A. Imarisio, S. Masciocchi, B. Bagni, E. Magni, M. Sessa, M. Turla, B. Ferraro, P. Trippa, A. Prelle, A. Ciccone, A. Padovani (Brescia, Italy)

    Objective: to evaluate the real-life use of internet and technological devices in parkinsonian patients Background: technology use is increasing in the ageing population but no…
  • MDS Virtual Congress 2021

    The course of tremor in de novo PD: 7 year longitudinal analysis

    J. Pasquini, N. Pavese (Milano, Italy)

    Objective: To longitudinally describe the course and clinical characteristics of tremor in Parkinson Disease (PD) over a seven-year follow up. Background: Tremor is a cardinal…
  • MDS Virtual Congress 2021

    Synchronous or asynchronous exercises is beneficial compared to no exercise in Brazilian people with Parkinson’s disease during COVID-19 pandemic.

    E. Tardelli, E. Okamoto, F. Tarallo, K. Tanaka, F. Santinelli, L. Simieli, E. Costa, F. Barbieri (São Paulo, Brazil)

    Objective: To compare the self-reported motor and non-motor symptoms in Brazilian people with Parkinson´s disease (PD) that performed home-based remotely exercise (asynchronous or synchronous) or…
  • MDS Virtual Congress 2021

    Optimizing an Electronic Health Records (EHR)-based Algorithm for Parkinson’s Disease Case Ascertainment

    A. Duarte Folle, L. Uhr, F. Agosta, T. Chang, C. Baddley, B. Ritz, C. Tanner, A. Wu, A. Wilson (Los Angeles, USA)

    Objective: To develop an EHR-based algorithm to classify patients with PD into three levels of diagnostic certainty. Background: EHRs can be a rich source of…
  • MDS Virtual Congress 2021

    Model Innovation in Parkinson’s disease drug development: linking Quantitative Systems Pharmacology to the patient voice

    J. Barrett, B. Piccoli, M. Muller, K. Barrett, D. Goncharov, C. Kaddi, K. Azer, K. Romero, D. Stephenson (Tucson, USA)

    Objective: There is a growing sense of urgency to integrate the voice of the patient in drug development in Parkinson’s disease (PD). Public private partnerships…
  • MDS Virtual Congress 2021

    Direct Costs of patients with Parkinson’s Disease in a region of the Brazilian Amazon

    R. Feio, T. França, A. Passos, A. Silva, A. Escudeiro, B. Koshimoto, D. Moura, B. Lobato (Belém, Brazil)

    Objective: To evaluate the perception of the annual direct costs (medications, medical appointments, rehabilitation, transportation) associated with the treatment for patients with PD in the…
  • MDS Virtual Congress 2021

    Trunk postural control in seated position on a prototype of unstable chair and the interference of cognitive and motor tasks in individuals with Parkinson disease

    H. Araújo, A. Miri, R. Volpe, M. Oliveira, R. Silva Jr, S. Smaili (Londrina, Brazil)

    Objective: To analyze trunk balance control of individuals with Parkinson disease (PD) in seated position and compare the control position with motor and cognitive tasks.…
  • MDS Virtual Congress 2021

    The EPSILON (Early ParkinSon wIth L-dopa/DDCi and OpicapoNe) study in early Parkinson’s disease: design and rationale of a phase III, double-blind, randomized, placebo-controlled study

    J. Ferreira, W. Poewe, O. Rascol, F. Stocchi, A. Antonini, J. Moreira, J. Rocha, P. Soares-da-Silva (Lisbon, Portugal)

    Objective: This study aims to explore the potential of opicapone (OPC) to enhance the clinical benefit of levodopa (L-dopa)/dopa decarboxylase inhibitor (DDCi) in patients with…
  • MDS Virtual Congress 2021

    CVT-301 (levodopa inhalation powder): meta-analysis of safety in patients with Parkinson’s disease (PD)

    P. Lewitt, P. Zhao, A. Corbin, D. Kegler-Ebo, B. Blank (West Bloomfield, USA)

    Objective: Safety results from a phase 3, double-blind study of CVT-301 in patients with PD were combined with results from a 4-week, phase 2b, double-blind,…
  • MDS Virtual Congress 2021

    Remote Art Therapy is feasible and may benefit individuals with Parkinson’s disease

    J. Rieders, K. Astudillo, D. Mania, R. Kilachand, M. Berberian, I. Acosta, A. Cucca, A. Feigin (New York, USA)

    Objective: To evaluate the feasibility of remote art therapy (rAT) for patients with Parkinson’s disease (PD), and compare psychosocial outcomes to in-person AT (ipAT). Background:…
  • « Previous Page
  • 1
  • …
  • 505
  • 506
  • 507
  • 508
  • 509
  • …
  • 553
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley